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Abstract 
This study investigates how both bioadhesive polymers (chitosan, hyaluronic acid and alginate) and 
permeability enhancers (ethylene glycol- bis(2-aminoethylether)- N, N, N', N'- tetraacetic acid 
(EGTA) and hydroxypropyl-ß-cyclodextrin) influence the permeability of the anti-glaucoma drug 
timolol maleate through ex vivo bovine corneas. Our results showed that only the permeability 
enhancers alone were able to increase drug permeability, whereas the polymers significantly 
reduced drug permeation, and however, they increased the pre-corneal residence of timolol. Ternary 
systems (polymer-enhancer-drug) showed a reduced drug permeability compared to the polymers 
alone. Fluorescence microscopy analysis of the epithelium surface confirmed there was no evidence 
of epithelial disruption caused by these formulations, suggesting that polymer-enhancer interactions 
 2 
reduce drug solubilization and counteract the disruptive effect of the permeability enhancers on the 
surface of the cornea. Further mucoadhesive tests, revealed a stable interaction of chitosan and 
hyaluronic acid with the epithelium, while alginate showed poor mucoadhesive properties. The 
differences in mucoadhesion correlated with the permeability of timolol maleate observed, i.e. 
formulations containing mucoadhesive polymers showed lower drug permeabilities. 
The results of the present study indicate polymers acting as an additional barrier towards drug 
permeability which is even more evident in the presence of permeability enhancers like EGTA and 
hydroxypropyl-ß-cyclodextrin. Then, this study highlights the need to adequately select additives 
intended for ocular applications since interactions between them can have opposite results to what 
expected in terms of drug permeability. 
1. Introduction 
The topical application of drugs is the most popular and well-accepted route of administration for 
the treatment of various eye conditions (Ludwig, 2005).  However, the bioavailability of ophthalmic 
drugs is very poor due to the effective protective mechanisms of the eye (Lee and Robinson, 1986),  
including blinking, lachrymation, and drainage (Ludwig, 2005). Therefore, frequent instillations of 
eye drops or high drug concentrations are needed to achieve therapeutic levels in the tissues 
(Andrés-Guerrero et al., 2011), which might induce toxic side effects and cellular damage at the 
ocular surface (Baudouin, 1996). In addition, the treatment of certain ocular diseases such as 
glaucoma follows the administration of combinations of two or more drugs (Bell et al., 2010), and 
therapies must be continued throughout the lifetime of the patient (Andrés-Guerrero, 2011), leading 
to a lack of patient's compliance. Glaucoma is the leading cause of irreversible blindness throughout 
the world and the lowering of intraocular pressure (IOP) at present is the only therapeutic approach 
proven to be successful (Lorenz and Pfeiffer, 2014). For many years now, ß-adrenergic receptor 
blocking agents (ß-blockers) have been the first choice for the treatment of ocular hypertension and 
primary open-angle glaucoma (Lorenz and Pfeiffer, 2014).  Timolol maleate is a nonselective ß-
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blocker (Brooks and Gillies, 1992) used alone or more frequently, in combination with other 
medicaments (García-López, 2014).  
Although in general, timolol is well tolerated by patients (Brooks and Gillies, 1992), approximately 
80% of topically administered eye drops is reported to drain through the nasolacrimal duct and is 
systemically absorbed (Shell, 1982). Therefore it is necessary to deepen research into new 
mechanisms focused on increasing the bioavailability of timolol at the ocular surface. In this regard, 
the use of bioadhesive polymers has been proposed as components of antiglaucoma formulations to 
reduce ocular toxicity, improve drug efficacy, and protect the ocular surface in long-term therapies 
(Andrés-Guerrero, 2011). Both the ability to increase the formulation viscosity (Saettone et al., 
1982) and the bioadhesive properties (Kaur and Smitha, 2002) of polymers were reported to reduce 
the drainage after instillation and therefore, increase the therapeutic efficacy of the ophthalmic 
drugs. The most common biopolymers used in the formulation of ocular solutions include natural, 
synthetic and semi-synthetic high molecular weight molecules (Kaur and Smitha, 2002), which are 
capable of forming strong noncovalent bonds with the mucin coating biological membranes 
(Almeida et al., 2014). Some examples of mucoadhesive polymers for ocular application are 
derivatives of cellulose (methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and 
hydroxyethylcellulose), polyvinyl alcohol (PVA), polyacrylic acid (PAA), chitosan, and hyaluronic 
acid. Nevertheless the biodegradability, biocompatibility and non-toxicity of the natural 
biopolymers, mainly glycosaminoglycans, make them excellent candidates for the development of 
drug delivery devices. 
Besides extending the residence time of the drug it is necessary to promote the permeability through 
the cornea using penetration enhancers or absorption promoters (Kaur and Smitha, 2002), in order 
to improve drug bioavailability. These compounds include some preservatives such as 
benzalkonium chloride and cetylpyridinium chloride that were reported to enhance penetration of 
some active compounds due to the disruption of the hydrophobic barrier of the corneal epithelium 
(Andrés-Guerrero, 2011). Surfactants, calcium chelators and cyclodextrins are among other 
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penetration enhancers commonly used in ocular formulations. Surfactants are incorporated into the 
lipid bilayer of the epithelium, resulting in the formation of mixed micelles that cause the removal 
of phospholipids and hence lead to membrane solubilization (Kaur and Smitha, 2002). Surfactants 
can also increase the paracellular transport of drugs by affecting the tight junctions between 
epithelial cells (Deli, 2009).  In the same way, calcium chelators disrupt the corneal epithelium by 
extracting Ca2+ ions (Kaur and Smitha, 2002) which are responsible for the maintenance of the 
effectiveness of the epithelium barrier. The polyaminocarboxylic acids ethylenediaminetetraacetic 
acid (EDTA) and its analogue ethylene glycol- bis(2-aminoethylether)- N, N, N', N'- tetraacetic acid 
(EGTA) have ion sequestering properties. Both calcium chelators were reported to reduce the 
electrical resistance of corneal membranes, confirming their ability to modify the barrier function, 
and to increase the corneal permeability of riboflavin in vitro (Morrison and Khutoryanskiy, 2014). 
Finally, cyclodextrins are oligosaccharides with a lipophilic central cavity and hydrophilic outer 
surface which are used as excipients in ocular formulations because of their ability to increase the 
water solubility of hydrophobic drugs (Loftsson and Stefánsson, 2002), such as riboflavin 
(Morrison et al., 2013). These authors proposed cyclodextrins are responsible for the extraction of 
cholesterol and other lipids from ocular cellular membrane being the reason for the observed 
increase in riboflavin permeability (Morrison et al., 2013). 
In the present study, we investigated the effect of different formulations containing biopolymers 
(hyaluronic acid, chitosan and alginate) and permeability enhancers (calcium chelators and 
cyclodextrins) on timolol maleate permeability through bovine cornea. We also analysed whether 
these formulations modified the corneal integrity and how their mucoadhesive properties affected 
the permeability of timolol. For a better comparison of results between treatments, we developed 
mathematical models to accurately quantify the apparent permeability of the drug and retention of 
the polymers on the corneal surface. 
2. Materials and methods 
 5 
2.1. Materials 
Timolol maleate was kindly supplied by Fine Chemicals Ltd (Dorset, United Kingdom). 
Triethylamine hydrochloride was purchased from Fluka. Chitosan medium molecular weight 
(190,000-310,000 Da, 75-85% deacetylation), sodium alginate medium viscosity (12,000-40,000 
Da), fluorescein isothiocyanate–dextran (FITC-dextran) 70,000 Da, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) and phosphoric acid were purchased from Sigma-Aldrich 
(Gillingham, United Kingdom). Hydroxypropyl-β-cyclodextrin (HP-ß-CD), and ethylene glycol-
bis(2-aminoethylether)- N,N,N',N' -tetraacetic acid (EGTA) were obtained from TCI Ltd (Oxford, 
United Kingdom). Hyaluronic acid was obtained by fermentation of Streptococcus zoeepidemicus 
ATCC 35246 (Amado et al., 2016), followed by acid hydrolysis using H3PO4 to a final MW of 
24,000 Da. Sodium chloride, potassium chloride, sodium phosphate, potassium dihydrogen 
phosphate, sodium hydroxide, Minisart syringe filters (0.2 μm), optimal cutting temperature 
compound (OCT) and methanol were obtained from Fisher Scientific (Hemel Hempstead, United 
Kingdom). Vectashield mounting medium with 4',6-diamidino-2-phenyl- indole (DAPI) was 
obtained from Vector Laboratories Ltd. (Peterborough, United Kingdom). 
2.2. HPLC analysis 
HPLC analysis was conducted using a PerkinElmer series 200 HPLC system comprising of 785 A 
UV-vis detector, series 200 quaternary pump and series 200 autosampler (PerkinElmer Inc., UK), 
Ascentis C18 column, 150 mm × 4.6 mm, 5 μm (part number: 581324-U) and data acquisition 
software (Peaksimple, version 4.09, SRI Inc., USA). Analysis of timolol maleate was achieved with 
a run time of 5 min using the method adapted from (El-Kamel, 2002). The mobile phase consisted 
of a mixture of methanol and triethylamine hydrochloride (45:55) under isocratic conditions, a flow 
rate was used at 1 mL min−1 at 30ºC and detected with a UV detector (295 nm). The retention time 
of timolol maleate was 2.85 min and the detection limit was 0.1 µM. Quantification of timolol 
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maleate concentration in the samples was achieved by linear interpolation in a calibration curve of 
timolol maleate standards at concentrations ranging from 0.28 to 2.8 µg mL−1. 
2.3. Preparation of animal tissues 
Bovine eyes were provided by PC Turners abattoirs (Farnborough, United Kingdom) and stored on 
ice during transport. The eyes were carefully handled and used whole or cornea dissected depending 
on the experiment. The corneas were dissected using a sharp blade with 2−3 mm of sclera attached, 
rinsed with PBS, and wrapped in a cling film to prevent dehydration. Fresh tissues were stored at 
4°C in a refrigerator and used within 48 h prior to experiments, preserved according to previous 
ocular drug permeability tests (Morrison et al., 2013; Morrison and Khutoryanskiy, 2014). 
Corneal sections from experiments were prepared by setting the cornea segment in OCT, quick 
freezing on dry ice, and subsequent microtome sectioning. Specimens were prepared for 
microscopy using a microtome (Bright, model 5040) within a cryostat (Bright, model OTF). 
Sections were cut at 7 μm, placed in groups of four on 75 mm × 25 mm glass slides, and dried 
gently using a hot air blower for 10 min from a distance of around 50 cm. The specimens were 
stained using Vectashield with DAPI mounting medium and a glass coverslip placed over the 
specimens. All cornea sections were examined within 48 h of preparation using an AXIOCAM 
MRm1.3 MP digital camera attached to a Zeiss AXIO Imager A1 fluorescent microscope, using 
AXIO Vs 40 V.4.8.2.0 software (Zeiss, Oberkochen, Germany). A 10× magnification eyepiece 
together with a 5× magnification objective lens was employed, and a light filter for DAPI 
fluorescence was selected. 
2.4. Transepithelial electric resistance (TEER) 
Formulations (Table 1) ability to modify the corneal barrier was assessed by TEER measurements 
which were carried out using adapted low volume (5 mL each side) Ussing chambers with an 
EVOM2 Epithelial Voltohmmeter and STX2 electrode (World Precision Instruments, Inc., USA) as 
reported in Morrison and Khutoryanskiy (2014). After an initial measurement (t0), resistance values 
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were recorded at 30 min intervals for 2 h and TEER values were calculated using the following 
equation: 
𝑇𝐸𝐸𝑅 = 𝑅 × 𝐴 1 
where R is the resistance in kΩ, and A is the area of the membrane in cm2. For better data 
comparison, TEER values were normalized (0-1) by dividing the resistance values at each time by 
the initial measurement of each series, which was recorded with corneal membrane just after the 
formulation was pipetted into the anterior chamber. 
2.5. Corneal permeability 
Table 1. Composition of the formulations containing chitosan (CH), alginate (AL), hyaluronic acid 
(HA), hydroxypropyl-β-cyclodextrin (HP-ß-CD), and glycol-bis(2-aminoethylether)- N, N, N', N' -
tetraacetic acid (EGTA) tested in this study. 
 
Formulation 
[Timolol] [Polymer] [Additive] 
 (mg mL-1)   (mg mL-1) (mg mL-1) 
        
Control 5 
 
– 
CH 5 1 – 
AL 5 1 – 
HA 5 1 – 
HP-ß-CD 5 – 30 
EGTA 5 – 1 
HA+HP-ß-CD 5 1 30 
AL+HP-ß-CD 5 1 30 
CH+HP-ß-CD 5 1 30 
HA+EGTA 5 1 1 
AL+EGTA 5 1 1 
CH+EGTA 5 1 1 
    
 
The effect of different formulations (Table 1) on corneal permeability of timolol maleate was 
studied in vitro using Franz diffusion cells. Polymer solutions (1 mg mL-1) of sodium hyaluronate, 
chitosan and sodium alginate were prepared in PBS and tested alone or in combination with EGTA 
(5 mg mL-1) or HPß-CD (30 mg mL-1, Table 1). To prepare chitosan solutions in PBS, the 
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commercial polymer was completely dissolved in the minimal volume (~1 mL) of acetic acid 0.1M 
and then made up to the appropriate volume with PBS. Timolol was added at a concentration of 5 
mg mL-1. Bovine corneas were mounted between donor and receiver compartments of standard 
Franz diffusion cells, epithelium side facing uppermost. The receiver compartment was filled with 
PBS (16.5 mL), ensuring no air bubbles were trapped under the membrane. Experiments were 
conducted in a water bath and stirred at 37 ± 1°C to mimic physiological temperature at the corneal 
surface. One millilitre of the corresponding formulation containing timolol maleate was added to 
the donor compartment and then sealed with a cling film to prevent dehydration. Samples (0.3 mL) 
were taken every 30 min for 240 min, being replaced with PBS after each sampling time, followed 
by HPLC analysis of drug concentration. Experiments were carried out at least in triplicate using 
different corneas for each repeat. Apparent permeability and steady-state flux were calculated using 
the following equation: 
𝑃𝑎𝑝𝑝 =
Δ𝑄
(Δ𝑡 × 60 × 𝐴 × 𝐶0)
 2 
 
where Papp is the apparent permeability of timolol maleate across bovine cornea, Q is the total 
amount permeated at time t, ΔQ/Δt is the steady-state flux into the receiving solution (nmol min−1) 
and this is equal to the gradient of the linear portion of the graph, 60 is the minutes to seconds 
conversion rate, A is the area of exposed cornea (1.54 cm2), and C0 is the initial amount of drug 
added to the donor chamber. 
2.6. Synthesis of fluorescent labeled polymers 
FITC-chitosan was synthesized following our previously published protocol (Cook et al., 2011). 
Both anionic polymers, alginate and hyaluronic acid, were fluorescently labeled using 
fluoresceinamine (isomer I, Sigma-Aldrich) using a method adapted from Cook et al. (2015). A 
mass of fluorophore equivalent to react with a 10% of polymer carboxyl reactive groups (0.1 
equivalents) was added to a 1% (w/v) polymer solution in PBS. Prior to the addition of the 
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fluoresceinamine, the carboxyl groups were activated by the addition of EDC (0.1 equivalents) and 
Sulfo-NHS (0.2 equivalents), at pH 6.0. They were mixed for approximately 15 min prior to 
dropwise addition of a solution of fluorophore in methanol (1 mL) and pH adjustment to 7.0. The 
reaction was allowed to proceed 24 h in the dark at room temperature and then dialyzed against 4 L 
of deionized water in the dark until fluresceinamine was not present in the dialysate. The resulting 
product was freeze-dried (Heto Power Dry LL 3000 freeze-drier, Thermo Electron Corporation) and 
kept wrapped in aluminum foil to avoid exposure to light. 
2.7. Corneal integrity 
The effect of different formulations containing fluorescently-labelled polymers alone or in 
combination with permeability enhancers on corneal integrity was investigated using the whole eye 
method (Morrison et al., 2013; Mun et al., 2014). Whole bovine eyes were placed in individual 150 
mL beakers, cornea facing uppermost. A Franz diffusion cell donor compartment was placed on the 
cornea and held in place using a cling film, ensuring a good seal at the corneal surface; the beakers 
were placed in a water bath at 37 ± 1°C and allowed to equilibrate for 30 min after which 1 mL of 
timolol solutions were added to the donor compartment. Corneas were exposed to the solutions for 
120 min and then sections were cut using a microtome and analysed using fluorescence microscopy, 
as described above. 
2.8. Polymer retention test 
The retention of polymers on bovine corneas was assessed using a method modified from previous 
published procedures (Al Khateb et al., 2016; Cave et al., 2012). Extracted cornea was mounted on 
a glass slide and incubated at 37°C for 5 min, and then 200 µL sample of fluorescently-labelled 
polymer or FITC-dextran (1 mg mL-1) was pipetted onto the surface of the cornea, placing the slide 
into a sloped channel at 37°C. The tissue was washed by dripping simulated tear fluid (STF: 6.78 g 
L-1 NaCl, 2.18 g L-1 NaHCO3, 0.084 g L
-1 CaCl2, and 1.38 g L
-1 KCl, adjusted to pH 7.4 with HCl) 
using a syringe pump at a constant flow rate. At pre-defined intervals, fluorescence images of the 
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whole tissue were acquired using Leica DFC3000G digital camera attached to a Leica MZ10F 
stereo-microscope (Leica Microsystems, Germany) fitted with a GFP filter and Leica Application 
Suit (LAS) software (version 4.4.0). The fluorescence images were analysed using ImageJ (version 
1.46r) to measure the total pixel intensity of the images. The background pixel intensity 
corresponding to an image of the cornea without the polymers was subtracted from each 
measurement. Fluorescence data was normalised (%) by dividing the fluorescence recorded at each 
time by the initial value taken after polymer exposure, and percentage fluorescence was modeled 
using Equation (4) written below. 
2.9. Mathematical models 
2.9.1. Drug permeability 
Logistic equations are widely accepted models for the description of drug dissolution kinetics 
(Zhang et al., 2010). In this case, we used a logistic equation where all parameters had biological 
meaning and the lag-time after which the permeation of timolol occurred could be directly obtained 
from the equation as the intersection of the tangent at the inflection point with the abscissa axis 
(Vázquez and Murado, 2008). The equation is similar to the logistic equation reported in Zhang et 
al. (2010) as one of the models included in the DDSolver software for the description of drug 
dissolution profiles, and was taken from Vázquez and Murado (2008): 
𝑄 =
𝑄𝑚
1 + 𝑒𝑥𝑝(2 +
4 × 𝜈𝑚 × (𝜆 − 𝑡)
𝑄𝑚
)
 
3 
 
where Q is the total amount of drug permeated at time t, Qmax is the maximum amount of drug 
permeated, νm is the maximum rate of drug permeation and equals the steady-state flux (ΔQ/Δt) into 
the receiving solution (nmol min−1), and λ is the lag-time (min) after which the permeation of the 
drug begins. Fitting procedures and parametric estimations were carried out by minimizing the sum 
of quadratic differences between observed and model predicted values using the nonlinear least-
squares (quasi-Newton) method provided by the Solver macro of the Microsoft Excel 2011 
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spreadsheet for Mac (Microsoft, Redmond, WA, USA). Confidence intervals from the parametric 
estimates and consistency of mathematical models (Student's t and Fisher's F tests; α=0.05) were 
evaluated using the Solver Aid (Prikler, 2009). The Papp was then calculated by substituting the 
steady-state flux obtained from Equation (3) in Equation (2). 
2.9.2 Polymer retention 
The polymer retention data from fluorescence images quantified via ImageJ and normalized as 
percentage, were adjusted using the following two-phase decay equation: 
𝐹 = 𝐹𝑃 + 100 × [𝑓 × 𝑒𝑥𝑝(−𝑘𝑓. 𝑡) + (1 − 𝑓)
× (−𝑘𝑠. 𝑡)] 
4 
 
where F is the remaining fluorescence (%) after a time t, FP is the plateau (%) that represents the 
remaining fluorescence at infinite t, f is the percentage of polymer that is washed-off faster, kf is the 
fast wash-off rate (min-1), and ks is the slow wash-off rate (min
-1). Plotting, data fitting and 
parametric estimations (Student’s t- test, 𝛼 = 0.05) were performed using the GraphPad Prism TM5 
(GraphPad Software Inc., San Diego, CA, USA). 
2. Results and discussion 
2.1. Trans-corneal permeability of timolol maleate 
The corneal epithelium constitutes the anterior layer of the eye, being the major barrier to ocular 
drug permeability. The epithelium lipophilic nature contributes to around 90% resistance to 
hydrophilic drugs and 10% to hydrophobic drugs (Washington et al., 2001; Wilson et al., 2001). 
Timolol maleate is soluble in water (Aggarwal and Kaur, 2005) and therefore has a low 
permeability into the cornea, being rapidly cleared due to nasolacrimal drainage. The drug loss 
leads to a systemic absorption that may cause respiratory and cardiovascular side effects, and hence 
it is necessary to find alternatives to enhance the ocular bioavailability of timolol maleate (El-
Kamel, 2002). In this paper, we studied the effect of different biopolymers (hyaluronic acid, 
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alginate and chitosan) and permeability enhancers (EGTA and HP-ß-cyclodextrin) on the 
permeability of timolol maleate. For this purpose, we used fresh bovine cornea preserved in the 
same conditions as previously published papers on the permeability of riboflavin (Morrison et al., 
2013; Morrison and Khutoryanskiy, 2014).  
 
 
 
 
 
 
 
 
 
Figure 1. Permeability of timolol maleate (5 mg mL-1) solutions through bovine cornea. Timolol 
solutions alone () or in combination with 5 mg mL-1 EGTA () and 30 mg mL -1 HP--CD () 
were tested. Control series in PBS (A), and formulations containing 1 mg mL-1 hyaluronic acid (B), 
alginate (C) or chitosan (D) are shown. Error bars correspond to triplicate measurements of drug 
concentration in the receiving solution of Franz diffusion cells through cornea permeation. Lines 
represent the fitting of Equation (3) to the experimental data. 
 
The permeation of the drug showed a lag-time of around 90 min before it was detected in the 
receiving solution of Franz diffusion cells (Figure 1). In accordance with previous observations, this 
lag time is a consequence of the diffusion of the drug into the cornea before it can be detected in the 
receiving solution. As a result of this lag-phase, timolol permeability kinetics showed sigmoidal 
curves in all cases (Figure 1). The calculation of Papp usually disregards the initial lag-phase of the 
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curve, and the permeability is calculated from the steady-state flux (Equation 2), which is the slope 
of the linear portion of the curve. Although this is a general procedure for calculating the 
permeability parameters in drug delivery systems, nonlinear adjustment is a preferred alternative 
when there is a delay in drug permeation, because it avoids selecting the linear portion of the graph, 
reducing the subjectivity of the analysis. In this study, the logistic equation utilized (Vázquez and 
Murado, 2008) adequately described the permeability of timolol maleate through bovine corneas 
(Fisher's F-test, 𝛼=0.05), and parameter estimations were almost always significant (Student's t-test, 
𝛼=0.05). Besides, the correlation coefficients between observed and expected values (r2) were 
higher than 0.98, whereas the linear model provided values as low as 0.93 (Table 2). In addition, the 
use of nonlinear regression has the advantage of explicitly providing the lag-time as a one of the 
parameters of the equation which, again, avoids a subjective analysis of the permeability kinetics.  
The concentration of timolol maleate in additive-free solution recorded after 240 min of corneal 
contact was 1.37 µg mL-1 (Figure 1 A). The apparent permeability (Papp) of timolol through bovine 
corneas was significantly enhanced in solutions containing EGTA (5 mg mL-1) and HP-ß-CD (30 
mg mL-1) when compared to timolol in PBS (Table 2), but none of the polymers provided 
improvement in drug permeation (Figure 1 B, C and D). Both EGTA and HP-ß-CD increased the 
Papp (p<0.01, one-way ANOVA) of timolol to 1.46 and 1.32 × 10-6 cm s-1, respectively, compared 
to the control (0.46 × 10-6 cm s-1). Besides, according to nonlinear adjustment, both formulations 
significantly increased (p<0.001) the maximal amount of drug permeated and the steady-state flux 
into the receiving solution (Table 2). These results are in agreement with previous reports showing 
enhanced permeability of riboflavin through bovine cornea in formulations containing calcium 
sequestering compounds (Morrison and Khutoryanskiy, 2014), and cyclodextrins (Morrison et al., 
2013) at the same concentration as those used in the present study. Also, a recent study found a 
formulation combining 𝛼-CD and EDTA was characterized by a significantly higher permeation of 
cysteamine across the cornea (Pescina et al., 2016), compared to benzalkonium chloride containing 
solution. The damage caused by both calcium chelators and cyclodextrins in the ocular surface is 
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most likely responsible for the improved permeability of timolol maleate. Actually, cyclodextrins 
are well-known disruptors of the integrity of the epithelium, increasing the permeability of low 
molecular weight molecules (Mun et al., 2014), such as timolol maleate (316.4 Da). 
The addition of 1 mg mL-1 solutions of hyaluronic acid, alginate or chitosan to timolol formulations 
reduced drug permeation, lowering the maximal amount of permeated drug, and decreasing the 
steady-state flux through the cornea (Table 2). The lower timolol permeability was particularly 
unexpected in solutions containing chitosan, since this cationic polymer is reported to have 
permeability enhancer properties (Di Colo et al., 2008), as well as the ability to induce reversible 
opening of tight junctions in epithelial cell models (McEwan et al., 1993; Ranaldi et al., 2002). 
Hyaluronic acid was also reported to enhance the permeability of acyclovir through buccal, vaginal 
and intestinal cell models (Sandri et al., 2004), and to enhance drug absorption through the skin due 
to the increased hydration of the outer layers of the skin (Brown et al., 2005). The addition of 
polymers to timolol formulations also increased the lag-time (p>0.05, one-way ANOVA) of drug 
permeation from 85 min in PBS solution to more than 100 min in formulations containing 
hyaluronic acid and alginate (Table 2). The prolonged residence of formulations containing some 
polymers was reported to be due to both the increase in the viscosity of the solutions as well as their 
mucoadhesivity (Kaur and Smitha, 2002). The increase in the time taken to achieve a measurable 
drug concentration in the receptor compartment of Franz cells is due to the slower diffusion of the 
drug into the cornea, which would eventually imply an increase in the residence time of the drug. 
Despite the pre-corneal prolonged residence time of timolol not being translated into an increased 
permeability through the cornea, the longer contact time with the eye could be an opportunity for 
the absorption through other routes. For instance, timolol like other ß-blockers, was reported to 
have better permeability through the conjunctiva (Ashton et al., 1991), and this could be an 
alternative absorption route for this compound.
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Table 2. Paremeters of timolol maleate permeability through bovine cornea in the presence of different formulations containing polymers, 
cyclodextrins and chelating agents. Mean and confidence intervals of linear (Equation (2)) and non-linear (Equation (3)) adjustment of data are shown. 
Formulation 
Linear  Non-linear  
         Q/t Papp x 10-6 
R2 
 Qm vm  Papp x 106 
R2 
(nmol min-1) (cm s-1)  (nmol) (nmol min-1) (min) (cm s-1) 
          
PBS 0.350.09 0.320.09 0.991  81.524.1 0.460.09 85.019.4 0.430.08 0.991 
HA 0.170.02 0.160.02 0.986  39.013.8 0.220.09 108.937.7 0.200.08 0.978 
AL 0.260.01 0.240.01 0.994  62.318.8 0.340.11 116.729.9 0.320.10 0.987 
CH 0.270.01 0.250.01 0.991  57.927.1 0.340.11 88.330.5 0.320.10 0.986 
EGTA 1.210.12 1.140.12 0.995  266.211.6 1.560.47 85.828.0 1.460.44 0.984 
HA+EGTA 0.070.001 0.070.001 0.960  40.7 (NS) 0.17 (NS) 166.3(NS) 0.16 (NS) 0.989 
AL+EGTA 0.130.02 0.120.001 0.975  26.610.9 0.160.05 82.729.2 0.150.05 0.983 
CH+EGTA 0.150.04 0.140.04 0.975  36.814.2 0.190.03 96.021.1 0.180.03 0.996 
HPßCD 0.830.05 0.770.05 0.930  161.815.8 1.410.37 64.513.8 1.320.34 0.995 
HA+HPßCD 0.070.01 0.070.01 0.986  17.28.3 0.090.03 81.129.4 0.090.02 0.983 
AL+HPßCD 0.120.04 0.110.03 0.986  24.86.4 0.140.02  81.417.2 0.130.03 0.994 
CH+HPßCD 0.150.02 0.140.02 0.940  64.6 (NS) 0.29 (NS) 149.8  37.4 0.27 (NS) 0.995 
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The formulations containing mucoadhesive polymers together with EGTA or HP-𝛽-CD 
significantly reduced (p<0.001, one-way ANOVA) the permeability of timolol compared to the 
permeability enhancers alone (Table 2). The Papp in ternary (timolol-polymer-enhancer) solutions 
was reduced from 1.4610-6 cm s-1 in polymer-free solution to 0.15 10-6 and 0.18 10-6 cm s-1 
(Table 2) in alginate and chitosan solutions, respectively. The maximum amount of drug permeated 
(p<0.001) and the steady-state flux (p<0.001) were also significantly reduced in EGTA and HP-𝛽-
CD polymer-containing solutions. This might be due to the polymeric nature of chitosan, which was 
reported to reduce the ability of cyclodextrins (𝛽-CD and HP-𝛽-CD) to form complex with drugs 
bearing different physicochemical properties, being the polymer-cyclodextrin interaction 
responsible for the reduced drug solubilization observed (Mura et al., 2007). In accordance with this 
observation, the interactions between cyclodextrin and chitosan, demonstrated by ATR-FTIR 
studies, were found to reduce the release rate of cyclosporine A from chitosan films intended for 
ocular application (Jug et al., 2012). Therefore, the reported interaction of HP-𝛽-cyclodextrin with 
chitosan, but also of alginate (Burckbuchler et al., 2006) and other polymers (Harada et al., 2014) 
might explain the unexpected lower timolol permeability observed in ternary systems compared to 
binary systems (timolol-polymer, Figure 1). 
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Figure 2. TEER measurements for exposed corneas to: PBS (), 5 mg mL-1 EGTA () and 30 mg 
mL-1 HP--CD () solutions alone (A) or containing 1 mg mL-1 solutions of hyaluronic acid (B), 
alginate (C) and chitosan (D). Error bars correspond to triplicate TEER values of exposed bovine 
cornea through Ussing chambers. Baseline resistance of PBS solution in the experiment cells 
without a membrane was 0.254  0.03 k, calculated from the TEER values from Equation (1). 
 
These findings correlate well with the TEER values for HP-𝛽-CD and hyaluronic acid solution 
increasing over 120 min, showing a significant increase (p<0.001, one-way ANOVA) in final 
TEER measurements (Figure 2). The increment in TEER value corresponds to a less permeable 
membrane (Morrison and Khutoryanskiy, 2014), and supports the significantly lower permeability 
of timolol observed (Table 2). The initial TEER values recorded for bovine corneas were between 
2.16 and 2.50 k cm2 which is in good agreement with previous results (Morrison and 
Khutoryanskiy, 2014). We observed a reduction of electrical resistance for corneas exposed to PBS 
from 2.530.03 to 2.200.10 k cm2 over 2 h, representing a 13% reduction, due to the corneal 
swelling observed when using in vitro techniques (Morrison and Khutoryanskiy, 2014). 
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2.2. Barrier function of the corneal epithelium 
A further experiment was conducted to test the effect of the solutions containing the polymers alone 
and with permeability enhancers (HP-ß-CD or EGTA), on the barrier function of the corneal 
epithelium. For this purpose fluorescently-labeled polymer solutions were put in contact with whole 
bovine eyes for 2 h, and then dissected corneas from the whole eye were sectioned and examined 
using fluorescence microscopy. The whole eye method was developed to study histological changes 
in the cornea, but avoiding the corneal swelling and the development of structural changes in 
dissected tissues with time (Morrison and Khutoryanskiy, 2014). Therefore, we followed this 
methodology because it was shown to reduce potential artifacts occurring when using Franz 
diffusion cells, and provides experimental in vitro conditions closer to in vivo models (Mun et al., 
2014). 
Figure 3 compares images of bovine cornea treated with polymers alone or combined with HP-β-
CD or EGTA. Aqueous cyclodextrins (Morrison et al., 2013; Mun et al., 2014) and calcium 
sequestering compounds (Morrison and Khutoryanskiy, 2014) solutions have shown to disrupt the 
corneal epithelium integrity by different mechanisms that make the corneal barrier less resistant to 
drug permeation. This phenomenon was observed to be time-dependent for cyclodextrins, and was 
evident only after 15 min of corneal exposure (Morrison et al., 2013). However, applying solutions 
containing any of these permeability enhancers combined with either hyaluronic acid, chitosan or 
alginate on the corneal surface for 2 h showed no evidence of epithelial disruption (Figure 3). 
Besides, fluorescence microscopy images of all the treatments tested showed polymer solutions 
were only observed on the corneal surface, confirming the integrity of the cornea was not disrupted 
for these large molecules to penetrate. These observations confirm previously reported data where 
the exposure of the cornea to either FITC-dextran (4,000 Da) or PEG (5,000 Da) did not 
demonstrate any permeation enhancement of these compounds after 1 h pre-treatment with 𝛽-
cyclodextrin (Mun et al., 2014). These results might suggest epithelial disruption caused by ß-
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cyclodextrins and EGTA is not sufficiently severe for high molecular weight molecules to 
penetrate. 
 
 
Figure 3. Exemplar fluorescence micrographs of cross section of bovine cornea exposed to 
formulations containing chitosan (a), hyaluronic acid (b) and alginate (c) alone and in combination 
with EGTA and HP-ß-CD. Corneas were exposed to the formulations for 2 h and each experiment 
was performed in triplicate using different eyes. Size bar: 100 μm.  
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Like other mucosal tissues of the human body, the ocular epithelial cells are coated with mucins 
which are high-molecular-weight glycoproteins forming a highly hydrated viscoelastic gel layer 
(Khutoryanskiy, 2010). This film forms a continuous fluid layer over the cornea which acts as a 
barrier that keeps it moist, protects it from bacterial invasiveness, and prevents foreign bodies from 
entering into the eye (Mun et al., 2014). The hydrophilic polymers containing charged functional 
groups such as those utilized in the present study are known to form non-covalent interactions with 
amino and sialic groups of mucins (Khutoryanskiy, 2010). Recently, new techniques like surface 
plasmon resonance have provided increased knowledge of the interactions between mucins and 
adhesive biopolymers, and suggest they may contribute to enhanced retention on apical membranes 
(Bravo-Osuna, 2012). In agreement with this hypothesis, the polymer-epithelial interactions 
together with the reduced permeability of timolol maleate observed in vitro, suggest that polymers 
might constitute an additional barrier towards drug permeation through bovine cornea. The 
entanglement of polymer chains would form a network reducing drug diffusion, as the higher lag-
time of drug permeation in the presence of polymers confirmed (Table 2). 
Hyaluronic acid (Ho et al., 2013) and chitosan (Fang et al., 2014) have wound healing properties of 
the ocular epithelium and are commonly used to treat "dry-eye" syndrome. Indeed, adhesive 
biopolymers are typically included in ocular drug formulations due to their anti-oxidative properties 
that counteract epithelial damage caused by preservatives used in ocular formulations (Debbasch et 
al., 2002). In the same way, we found the addition of permeability enhancers in the presence of 
polymers had no effect on the corneal integrity (Figure 3). This result suggests the polymer-
enhancer interaction counteracting the disruptive effect of EGTA or cyclodextrins on the corneal 
surface. The latter hypothesis is more likely to be responsible for this phenomenon because it also 
supports the reduced timolol permeability observed in ternary systems compared to binary systems, 
as explained before. In the same way, previous reports have found reduced drug diffusion and 
swelling as a result of the formation of a compact matrix due to chitosan-cyclodextrin interactions 
(Hermans et al., 2014; Jug et al., 2012). 
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These findings correlate with the above-discussed results where it was found that polymers reduced 
timolol maleate permeability upon corneal exposure, whereas the permeability enhancers, when 
incorporated in the polymers, reduced the permeability significantly more. 
2.3. Mucoadhesive properties of polymers 
In order to compare the mucoadhesive properties of the biopolymers, their retention on ex vivo 
bovine corneas was assessed according to the methodology described in Al Khateb et al. (2016) 
(Figure 4). The retention of the fluorescently-labelled polymers on bovine cornea during washing 
with STF was determined using fluorescence microscopy, and FITC-dextran was used as a non-
mucoadhesive polymer (negative control). The exponential decrease in fluorescence after washing 
was modeled using a two-phase decay equation that considers a first stage of rapid washing of the 
non-retained polymers, and a second phase when polymers attached to the mucosa are washed 
slower. The agreement between predicted and experimental data was excellent (Figure 4), with R2 
values higher than 0.948. The p-values from Fisher's F -test also indicated Equation (4) consistently 
described the wash-off data from images, quantified via ImageJ. 
The results showed that all polymers (p<0.05, one-way ANOVA) were retained significantly longer 
on the corneas than the control, suggesting they all bear certain mucoadhesive properties. 
According to parametric estimation, the wash-off rate corresponding to the greater retained fraction 
of polymer (ks) was significantly slower for hyaluronan (p=0.021, t-test) and chitosan (p=0.016, t-
test) compared to the control (Figure 4). The retention profiles of chitosan and hyaluronic acid 
suggest a stable adhesion process with the corneal epithelium, although their different behaviour 
indicate the nature of these interactions might be different. Chitosan has been reported to bind 
mucin via ionic interaction between primary amino groups of the glycan and the sialic and 
sulphonic acid groups of mucins (Bravo-Osuna et al., 2012), together with hydrogen bonding 
through the interaction of the hydroxyl and amino groups of chitosan (Sogias  et al., 2008). On the 
contrary, it was found that hyaluronic acid needs the development of prior chain inter-diffusion with 
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mucin molecules in addition to hydrogen bonding to promote the formation of a sufficiently stable 
interaction with the ocular epithelium (Bravo-Osuna et al., 2012).  
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Figure 4. Retention kinetics of fluorescently labelled polymers and FITC-dextran (negative control) on ex vivo bovine cornea. Data (symbols) are the 
mean of triplicate samples (n = 3) and standard deviation (error bars). The lines are the fitting of Equation (4) to experimental data. Parameter 
estimations (mean and confidence intervals,  =0.05) and correlation coefficients (r2) are shown. The green box represents the plateau (FP) or the 
remaining fluorescent (%) after infinite washing.  
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This mechanism of interaction could potentially facilitate a better retention of hyaluronic acid on 
the ocular mucosa compared to chitosan. Indeed, the percentage of hyaluronic acid bound after 
infinite wash (Fp) was 30.4%, while a 18.8% of chitosan and a 12.7 % of alginate remained attached 
to the corneal epithelium (Figure 4). The more stable interaction of hyaluronic acid was then 
reflected in a significantly higher retention than chitosan (p=0.027, t-test) and alginate (p=0.005). 
The poorer mucoadhesive properties of alginate is in accordance with previous reports showing this 
polymer exhibits weaker interactions with mucins compared to other biopolymers, such as chitosan 
(Haugstad et al., 2015). 
Interestingly, the differences in mucoadhesion correlated well with the observed permeability of 
timolol maleate through bovine cornea; in such a way that, the higher the mucoadhesivity of the 
polymer, the lower the permeability of the drug through the cornea (Table 2). Nevertheless, longer 
corneal retention may enhance bioavailability by other routes of absorption in addition to the 
corneal pathway. 
Conclusions 
The addition of permeability enhancers (EGTA and HP-ß-CD) improved the permeation of timolol 
maleate through bovine cornea, in accordance with previous reports. However, timolol formulations 
containing bioadhesive polymers (hyaluronic acid, chitosan, alginate) alone or together with both 
permeability enhancers were found to lower drug permeation. Fluorescence microscopy analysis of 
the epithelium surface did not establish any evidence of epithelial disruption after 2 h of treatment 
with EGTA or HP-ß-CD combined with the polymers, suggesting that the polymer-enhancer 
interactions reduce drug solubilization and counteract the disruptive effect of the permeability 
enhancers on the surface of the cornea. Besides, the fluorescently-labelled polymers were only 
observed on the surface of the cornea, confirming that there was no sufficient disruption of the 
epithelium for the biopolymers to penetrate. 
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On the other hand, mucoadhesive studies revealed a stable interaction of chitosan and hyaluronic 
acid with the epithelium, while alginate showed poor mucoadhesive properties. The different 
retention profiles of chitosan and hyaluronic acid suggest the nature of the interaction with mucins 
is different. This is in agreement with previous research indicating chitosan-mucin interactions are 
predominantly due to electrostatic attraction and hydrogen bonding, while hyaluronan-mucin stable 
interaction needs the development of chain-interdiffusion in addition to other non-covalent bonding. 
The differences in mucoadhesion correlated with the permeability of timolol maleate observed, i.e. 
formulations containing greater quantities of mucoadhesive polymers showed lower drug 
permeabilities. 
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